Resveratrol is not a blood thinner in the traditional sense, but it does have measurable anti-platelet effects that reduce clotting. It works through some of the same pathways as aspirin, suppressing the chemical signals that tell platelets to clump together. At supplement-level doses, these effects are significant enough that hospitals list resveratrol among supplements to stop before surgery, and clinical trials exclude participants taking blood-thinning medications because of the interaction risk.
How Resveratrol Affects Clotting
Traditional blood thinners like warfarin work by interfering with clotting factors, the proteins in your blood that build a clot. Resveratrol does something different. It targets platelets, the tiny cell fragments that stick together as the first step in forming a clot. That makes it more comparable to aspirin or clopidogrel than to warfarin, though it’s weaker than either.
Resveratrol reduces platelet clumping through two main routes. First, it blocks an enzyme called COX-1, which is the same enzyme aspirin blocks. This suppresses the production of a signaling molecule (thromboxane A2) that normally tells nearby platelets to activate and aggregate. Second, it interferes with the way platelets physically stick to damaged blood vessel walls by disrupting a key binding interaction between a protein in your blood and a receptor on the platelet surface. Lab studies on human blood show that resveratrol also slows down platelet metabolism overall, reducing their energy consumption and reactivity.
What the Human Evidence Shows
Most of the strongest data comes from lab studies using human blood samples rather than long-term clinical trials. In one study on blood from people with type 2 diabetes, resveratrol reduced clot formation by over 50% in both healthy and diabetic blood samples. It also cut thromboxane A2 release by 38% in healthy platelets and by 79% in diabetic platelets. Diabetic blood tends to be more clot-prone to begin with (thromboxane production was 47% higher in diabetic platelets than healthy ones), which may explain why resveratrol’s effects were more dramatic in that group.
A separate study looked specifically at patients whose platelets didn’t respond well to aspirin, a condition affecting up to 20% of high-risk cardiac patients. Resveratrol significantly reduced platelet aggregation triggered by collagen and epinephrine in these aspirin-resistant patients, while having only marginal effects in patients whose platelets already responded to aspirin. This suggests resveratrol may work through partially overlapping but not identical pathways to aspirin.
In a clinical study of healthy postmenopausal women, a single 90 mg dose of resveratrol reduced platelet reactivity compared to baseline. However, large-scale trials measuring real-world outcomes like heart attacks or strokes from resveratrol’s anti-platelet effects haven’t been conducted.
Red Wine vs. Supplements
If you’re wondering whether a glass of red wine delivers enough resveratrol to thin your blood, the answer is effectively no. Red wine contains roughly 2 mg of resveratrol per liter. A standard glass (150 ml) provides about 0.3 mg. The average wine drinker consumes around 0.2 mg of resveratrol per day from wine alone, which is roughly 5,000 times less than the 1 gram doses used in some clinical trials.
Supplements are a completely different story. Commercial resveratrol capsules commonly contain 250 mg to 1,000 mg per dose, putting them firmly in the range where anti-platelet effects have been observed in studies. Even the lower end of supplement dosing (90 mg in one clinical study) was enough to measurably change platelet behavior. The gap between dietary intake and supplement doses is enormous, and the anti-clotting concern applies almost exclusively to supplements.
Interactions With Blood-Thinning Medications
Clinical researchers take resveratrol’s blood-thinning properties seriously enough to screen for them. A cardiovascular trial at ClinicalTrials.gov excluded participants taking any of the following due to potential interactions with resveratrol:
- Aspirin above 81 mg daily
- Prescription anticoagulants including warfarin, rivaroxaban, dabigatran, apixaban, and heparin
- Antiplatelet drugs like clopidogrel
- Daily NSAIDs such as ibuprofen and naproxen
The concern is additive. If you’re already on a medication that reduces clotting, adding resveratrol could push the combined effect into a range where bleeding risk increases. This is particularly relevant because resveratrol has a plasma half-life of about 9 hours, meaning it stays active in your system for most of the day after a single dose. Despite being absorbed well (at least 70% of an oral dose), its overall bioavailability is low because the body rapidly converts it into metabolites. But those metabolites and the parent compound together still circulate at meaningful levels for hours.
Stopping Before Surgery
The University of Washington Medical Center includes resveratrol on its list of supplements to stop seven days before surgery. This is standard practice across many hospital systems. The seven-day window is a precaution that applies broadly to herbal products, natural supplements, and vitamins that may affect bleeding. Given resveratrol’s documented effects on platelet aggregation, this recommendation is well-supported.
If you have a scheduled procedure, the simplest approach is to stop resveratrol supplements a full week beforehand. Because the half-life is only about 9 hours, the compound itself clears quickly, but the conservative window accounts for cumulative effects on platelet function and individual variation in metabolism.
How It Compares to Aspirin
Resveratrol is weaker than low-dose aspirin as an anti-platelet agent. Aspirin irreversibly disables COX-1 in every platelet it reaches, and since platelets can’t make new proteins, that platelet is permanently affected for its entire 7 to 10 day lifespan. Resveratrol’s inhibition of COX-1 is reversible, so its effects fade as the compound is cleared from your blood.
Where resveratrol shows a distinct effect is in people whose platelets don’t respond to aspirin. In one study, resveratrol significantly reduced collagen-triggered aggregation in aspirin-resistant platelets while barely affecting platelets that already responded to aspirin. This suggests resveratrol may act through additional mechanisms beyond just COX-1 inhibition, potentially making it complementary rather than redundant to aspirin’s effects. That said, combining the two without medical guidance increases bleeding risk, which is why trials set aspirin cutoffs for participants taking resveratrol.